Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma Article Swipe

PDF

Related Concepts

Sorafenib Medicine Regorafenib Hepatocellular carcinoma Programmed cell death 1 Immunotherapy Lenvatinib Targeted therapy Oncology PD-L1 Cancer research Programmed cell death Internal medicine Cancer Apoptosis Colorectal cancer Biochemistry Chemistry

Linlin Zheng , Changcheng Tao , Zonggui Tao , Kai Zhang , Anke Wu , Jianxiong Wu , Weiqi Rong ·

YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.4240/wjgs.v13.i10.1136 · OA: W3208577316

In recent years, a number of targeted therapeutic agents have achieved success in phase III trials in patients with advanced hepatocellular carcinoma (HCC), including sorafenib, lenvatinib, and regorafenib. Immunotherapy is considered to be an effective treatment for advanced HCC. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) are important antitumor immunotherapy agents that represent breakthroughs in the treatment of advanced HCC. However, treating advanced HCC is still a great challenge, and the need for new treatments remains urgent. This review briefly summarizes the research progress in the use of PD-1/PD-L1 inhibitors combined with targeted therapy for treating HCC.